ArticleESC heart failure2019
Contrast-induced nephropathy after cardiac resynchronization therapy implant impairs the recovery of ejection fraction in responders.
Article in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Zero-contrast cardiac resynchronization therapy device implantation in heart failure patients with renal impairment.Heart rhythm O2 · 2026Article
- Feasibility, safety and outcomes of contrast-free cardiac resynchronisation therapy device implantation: a retrospective cohort comparison.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Novel predictive role of glomerular filtration rate in atrial fibrillation development among chronic heart failure patients.BMC cardiovascular disorders · 2025Article
- First demonstration of left bundle branch area pacemaker implantation guided by artificial intelligence electrocardiographic mapping.HeartRhythm case reports · 2025Article
- Understanding LOT-CRT: Current Insights, Limitations, and Our Center's Experience.Journal of clinical medicine · 2025Review
- The Role of ARNI in Enhancing Outcomes of Cardiac Resynchronization Therapy: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Clinical outcomes of His bundle pacing vs. right ventricular pacing in patients with conduction disturbances following transcatheter aortic valve replacement.BMC cardiovascular disorders · 2025Article
- Multipoint Left Ventricular Pacing as Alternative Approach in Cases of Biventricular Pacing Failure.Journal of clinical medicine · 2025Review
- Long-term benefits of single left ventricular pacing based on rate-adaptive atrioventricular delay algorithm in cardiac resynchronization therapy.Frontiers in cardiovascular medicine · 2025Article
- The Relationship Between the Kansas City Cardiomyopathy Questionnaire and Electrocardiographic Parameters in Predicting Outcomes After Cardiac Resynchronization Therapy.Life (Basel, Switzerland) · 2024Article
- Heart Rate Recovery Index and Improved Diastolic Dyssynchrony in Fusion Pacing Cardiac Resynchronization Therapy.Journal of clinical medicine · 2024Article
- Harmonizing Heartbeats: The Mosaic of Cardiac Resynchronization Therapy Responders-A Comprehensive Exploration of Diverse Criteria and Predictors.Journal of clinical medicine · 2024Article
- Left Atrium Reverse Remodeling in Fusion CRT Pacing: Implications in Cardiac Resynchronization Response and Atrial Fibrillation Incidence.Journal of clinical medicine · 2024Article
- Feasibility and safety of left bundle branch area pacing-cardiac resynchronization therapy in elderly patients.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2023Article
- Contrast-induced nephropathy after cardiac resynchronization therapy implant impairs the recovery of ejection fraction in responders.ESC heart failure · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsData regarding contrast-induced nephropathy (CIN) after cardiac resynchronization therapy (CRT) implant are limited. We aimed to investigate the incidence and determinants of CIN and its impact on CRT response and outcomes. METHODS AND
resultsPatients who underwent CRT implant were retrospectively analysed, and CIN was defined as an increase of serum creatinine ≥0.3 mg/dL or ≥1.5 times the baseline value. Response to CRT was defined as a reduction of left ventricle end-systolic volume (LVESV) of 15% or the increase of five percentage points in ejection fraction (EF) as assessed by echocardiography at 6 months. Follow-up visits were scheduled at 3, 6, and 12 months. Contrast-induced nephropathy occurred in 13/107 patients (12%). Among baseline clinical, echocardiographic, and laboratory characteristics, only a high baseline serum creatinine was associated with the occurrence of CIN. Symptoms, EF, and LVESV at 6 months improved in both CIN and non-CIN patients, and the rate of responders to CRT was similar. Among responders, at 6 months, those with CIN had significantly lower EF (28.5% vs. 35.7% P = 0.003). At a median follow-up of 112 weeks, 43% of patients experienced a clinical event with similar incidence in CIN and non-CIN patients, and likewise survival was similar. Non-responders to CRT had worse survival while among responders those with CIN had worse survival than non-CIN patients (71% vs. 90%, P = 0.0035).
conclusionsThe incidence of CIN is rather high. Although CIN does not influence response to CRT overall, however among responders impairs the recovery of EF and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.